Close Menu

NEW YORK – Cowen on Tuesday upgraded Hologic's stock to Outperform from Market Perform and increased the share-price target to $64 from $55.

In a research note, Cowen analyst Chris Lin said that largely as a result of demand for COVID-19 testing, Hologic is on track to place about 500 Panther systems this year, about double its recent annual run rate. "While these placements are primarily driven by COVID-19 testing needs in the near term, we believe labs will continue to utilize these instruments once COVID-19 testing abates," Lin said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.

Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.

Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.

In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.